MapLight Therapeutics, Inc.
NASDAQ:MPLTBiotechnology
+$0.39 today
- Market cap
- $283.41M
- Beta
- 2.65
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$4.41
Volume 0.42M
Average 0.73M
MPLT Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
MapLight Therapeutics, Inc.NASDAQ: MPLT
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity rises 330.0% from a year ago
Total equity stood at $399.83M at the end of Q1 FY2026, up 330.0% from a year earlier and down 12.8% from the prior quarter. Over 3 fiscal years it compounded at +180.0% a year.
Context
- Total equity amounted to 95.5% of total assets at the end of Q1 FY2026, up 12.1 pp from a year earlier.
- Total equity increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +330.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 458.37M USD
- Year-over-year change
- +297.9%
- 3-year CAGR
- +180.0%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 458.37M | +297.9% |
| FY2024 | 2024-12-31 | 115.2M | +61.6% |
| FY2023 | 2023-12-31 | 71.28M | +241.6% |
| FY2022 | 2022-12-31 | 20.87M | — |
Total Equity vs competitors
How MPLT compares with its peers on the latest reported figures
- MPLT's Mar 2026 total equity of $399.83M is the 3rd highest of the 11 companies compared; the peer median is $224.59M.
- Its year-over-year change of +330.0% is the 4th highest of 11, against a peer median of +70.0%.
- Total equity amounts to 95.5% of total assets for MPLT, versus a peer median of 92.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $968.03M | +641.2% | +30.1% | 90.1% |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $471.51M | +65.0% | +191.8% | 94.8% |
| Mar 2026 | $399.83M | +330.0% | +180.0% | 95.5% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $378.69M | +3546.2% | — | 96.2% |
| Mar 2026 | $263.38M | -15.1% | +3.8% | 95.7% | |
| Mar 2026 | $243.37M | +75.0% | — | 88.1% | |
| Mar 2026 | $205.8M | +401.7% | +27.2% | 73.9% | |
| Mar 2026 | $198.27M | +234.5% | -0.4% | 87.9% | |
| Dec 2025 | $126.62M | +14.2% | -12.7% | 95.2% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $70.68M | -69.0% | — | 45.9% |
| Jun 2026 | -$201.56B | -627630.4% | — | 212.0% | |
| Peer median (excluding MPLT) | $224.59M | +70.0% | +15.5% | 92.4% | |
Competitors are the stored peer set for MPLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MapLight Therapeutics, Inc.
NASDAQ:MPLT
Intrinsic Alpha fair value
Locked
Current Price
$6.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.